bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)
搜索文档
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
Benzinga· 2025-10-16 00:23
The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.In the MK-8591A-052 trial, the suppression was on bictegravir/emtricitabine/tenofovir alafenamidei (BIC/FTC/TAF) and baseline antiretroviral therapy (bART) in tri ...
Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection
Businesswire· 2025-10-15 18:45
Oct 15, 2025 6:45 AM Eastern Daylight Time Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection Share DOR/ISL data presented show minimal changes in weight and body composition and no clinically meaningful effect on fasting lipids and the homeostatic model assessment of insulin resistance (HOMA- IR) across clinical trials In the double-blind trial MK-8591A-052 ...